These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 10905795)

  • 1. Pharmacokinetics of argatroban in primates: evidence on endogenous uptake.
    Ahmad S; Yang LH; Ahsan A; Fu K; Iqbal O; Hoppensteadt DA; Lewis BE; Walenga JM; Fareed J
    Int Angiol; 2000 Jun; 19(2):126-34. PubMed ID: 10905795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals.
    Berry CN; Lunven C; Lecoffre C; Lainée P; O'Connor SE; André F; Roger B; Garrigou-Gadenne D; Rouchouse A; Roome NO; Vivan N
    Thromb Haemost; 2000 Aug; 84(2):278-85. PubMed ID: 10959701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications.
    Ahmad S; Ahsan A; George M; Iqbal O; Jeske WP; McKenna R; Lewis BE; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 1999 Oct; 5(4):252-8. PubMed ID: 10726023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
    Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
    J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods.
    Ahmad S; Iqbal O; Ahsan A; Hoppensteadt DA; Lewis BE; Walenga JM; Fareed J
    Int Angiol; 1999 Sep; 18(3):198-205. PubMed ID: 10688418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
    Berry CN; Girard D; Girardot C; Lochot S; Lunven C; Visconte C
    Semin Thromb Hemost; 1996; 22(3):233-41. PubMed ID: 8836007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.
    Tran JQ; Di Cicco RA; Sheth SB; Tucci M; Peng L; Jorkasky DK; Hursting MJ; Benincosa LJ
    J Clin Pharmacol; 1999 May; 39(5):513-9. PubMed ID: 10234600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.
    Swan SK; Hursting MJ
    Pharmacotherapy; 2000 Mar; 20(3):318-29. PubMed ID: 10730687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of locally administered argatroban on restenosis after balloon angioplasty: experimental and clinical study.
    Imanishi T; Arita M; Tomobuchi Y; Hamada M; Hano T; Nishio I
    Clin Exp Pharmacol Physiol; 1997 Nov; 24(11):800-6. PubMed ID: 9363360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose argatroban therapy for stroke: novel treatment for delayed treatment and the recanalization mechanism.
    Ishibashi H; Koide M; Obara S; Kumasaka Y; Tamura K
    J Stroke Cerebrovasc Dis; 2013 Jul; 22(5):656-60. PubMed ID: 22576008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Left heart bypass with the bio-medicus centrifugal pump by the use of an antithrombin agent, argatroban].
    Kawada T; Mieda T; Abe H; Kamata S; Nakamura S; Endo S; Kikuchi K; Miyamoto S; Nishimura K; Funaki S
    Kyobu Geka; 1994 Sep; 47(10):803-8. PubMed ID: 7933735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study.
    Scalambrino E; Padovan L; Chantarangkul V; Clerici M; Artoni A; Peyvandi F; Tripodi A
    Int J Lab Hematol; 2020 Jun; 42(3):e128-e131. PubMed ID: 32086868
    [No Abstract]   [Full Text] [Related]  

  • 13. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
    Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
    Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coagulation laboratory testing in patients treated with argatroban.
    Walenga JM; Fasanella AR; Iqbal O; Hoppensteadt DA; Ahmad S; Wallis DE; Bakhos M
    Semin Thromb Hemost; 1999; 25 Suppl 1():61-6. PubMed ID: 10357154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the efficacy of an antithrombin agent "Argatroban" combined with exercise therapy on increase of the skeletal muscle blood flow.
    Murata S; Kobayashi A; Takeuchi T; Nakajima H; Yoshida A; Kurosawa Y; Miki S; Mizoguchi T; Sakurai T; Kawatani A
    Nihon Geka Hokan; 1996 Jul; 65(3):109-19. PubMed ID: 9528269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of argatroban during multi-organ procurement: pharmacokinetics and sequelae in recipient of transplanted liver.
    Schwartz JJ; Hatch JM; Book Z; Lonardo N; Hutson WR; Sorensen JB
    Clin Transplant; 2009; 23(5):705-9. PubMed ID: 19637991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
    Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
    Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Examination of the Relationship between Worse Symptom and Differences Route during Administration of Argatroban in Acute Ischemic Stroke Patients].
    Sunaga T; Higashino M; Kimura A; Baba Y; Tanioka T; Watanabe T; Sasaki T
    Yakugaku Zasshi; 2020; 140(11):1373-1380. PubMed ID: 33132273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
    Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock.
    Beyer J; Halbritter K; Weise M; Schellong S
    Thromb Res; 2009 Jul; 124(3):383-6. PubMed ID: 19062078
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.